Pyxis Oncology's (PYXS) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Pyxis Oncology (NASDAQ:PYXS - Free Report) in a research note issued to investors on Monday,Benzinga reports. They currently have a $5.00 price objective on the stock. HC Wainwright also issued estimates for Pyxis Oncology's Q2 2025 earnings at ($0.36) EPS, Q3 2025 earnings at ($0.40) EPS, Q4 2025 earnings at ($0.45) EPS, FY2025 earnings at ($1.55) EPS, Q1 2026 earnings at ($0.46) EPS, Q2 2026 earnings at ($0.37) EPS, Q3 2026 earnings at ($0.37) EPS, Q4 2026 earnings at ($0.38) EPS, FY2026 earnings at ($1.46) EPS, FY2027 earnings at ($1.32) EPS, FY2028 earnings at ($0.60) EPS and FY2029 earnings at $0.18 EPS.

Separately, Royal Bank of Canada reaffirmed an "outperform" rating and set a $8.00 price objective on shares of Pyxis Oncology in a report on Wednesday, March 19th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $9.00.

Pyxis Oncology Price Performance

Shares of PYXS traded up $0.03 on Monday, hitting $1.23. The company's stock had a trading volume of 471,961 shares, compared to its average volume of 739,771. The company has a 50 day moving average price of $1.06 and a 200 day moving average price of $1.56. Pyxis Oncology has a fifty-two week low of $0.83 and a fifty-two week high of $5.39. The company has a market capitalization of $76.20 million, a PE ratio of -1.19 and a beta of 1.15.

Pyxis Oncology (NASDAQ:PYXS - Get Free Report) last posted its quarterly earnings data on Thursday, May 15th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by ($0.06). On average, equities analysts forecast that Pyxis Oncology will post -1.04 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Acadian Asset Management LLC acquired a new position in shares of Pyxis Oncology in the 1st quarter valued at $81,000. 683 Capital Management LLC increased its position in shares of Pyxis Oncology by 32.5% in the 1st quarter. 683 Capital Management LLC now owns 550,000 shares of the company's stock valued at $539,000 after buying an additional 135,000 shares in the last quarter. Nuveen LLC bought a new stake in shares of Pyxis Oncology in the 1st quarter valued at $125,000. Pier 88 Investment Partners LLC increased its position in shares of Pyxis Oncology by 296.6% in the 1st quarter. Pier 88 Investment Partners LLC now owns 390,960 shares of the company's stock valued at $383,000 after buying an additional 292,370 shares in the last quarter. Finally, Ridgeback Capital Investments L.P. bought a new stake in shares of Pyxis Oncology in the 4th quarter valued at $560,000. Institutional investors and hedge funds own 39.09% of the company's stock.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.